OXUR.BR Oxurion NV (EURONEXT) down 16.67% pre-market to €0.005 25 Mar 2026: watch April earnings

OXUR.BR stock plunged 16.67% pre-market to €0.005 on 25 Mar 2026 after heavy selling on EURONEXT, making it one of this session’s top losers. Trading volume hit 351105.00 shares versus a 50-day average of 360193.00, signaling active repositioning ahead of an earnings announcement on 03 Apr 2026. Investors should note the tiny market cap of €350492.00 and very low liquidity, which amplify volatility and execution risk for trades.

OXUR.BR stock market snapshot and price action

Oxurion NV (OXUR.BR) is trading on EURONEXT in Europe at €0.005 after a -16.67% move pre-market. The stock opened at €0.0056, recorded a day high of €0.0056 and a day low of €0.005. Average price over 50 days is €0.0063 and 200-day average is €0.01655, highlighting a sharp downtrend over longer time frames.

Drivers and catalysts for OXUR.BR stock

Primary near-term catalysts include the scheduled earnings release on 03 Apr 2026 and clinical readouts for THR-149 and THR-687 in diabetic macular edema programs. News or trial updates can trigger outsized moves given the small market cap and low float. We link to Oxurion’s corporate site for filings and program updates Oxurion website and to company posts on LinkedIn Oxurion LinkedIn.

OXUR.BR stock fundamentals and valuation snapshot

Trailing metrics show a market cap of €350492.00, EPS €2.23, and no meaningful PE ratio reported. Price-to-sales is 175.25 and enterprise value to sales is 5587.25, reflecting near-zero revenue and high enterprise value items. The company shows negative working capital (-€13,956,000.00) and a low current ratio 0.17, indicating short-term liquidity pressure and potential dilution risk.

Technical read: OXUR.BR stock is oversold but volatile

Momentum indicators point to oversold conditions: RSI 36.35 and MFI 14.71, with CCI -194.77. ADX at 28.60 signals a strong trend, currently downward. Trading volumes slightly below average (relVolume 0.97) suggest continued price pressure rather than a panic spike. Short-term technicals support caution for new long positions.

Meyka AI rating and OXUR.BR stock forecast

Meyka AI rates OXUR.BR with a score out of 100: 72.79 (B+) — BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. Meyka AI’s forecast model projects a yearly value of €320.61 and a three-year value of €347.98, which implies an extreme upside versus the current €0.005 price. These model outputs reflect statistical artifacts given the micro-cap size and should be treated cautiously. Forecasts are model-based projections and not guarantees.

Risk profile and trading strategy for OXUR.BR stock

Key risks include clinical trial failure, rapid dilution, and severe liquidity constraints given a market cap of €350492.00 and shares outstanding 70098394.00. For traders we suggest three scenario targets: conservative €0.01, base €0.02, and aggressive €0.05 price targets tied to positive clinical or earnings news. Use tight size limits, limit orders, and expect wide spreads on EURONEXT.

Final Thoughts

OXUR.BR stock is a clear pre-market top loser on 25 Mar 2026 after the price fell to €0.005, driven by thin liquidity and investor repositioning ahead of an earnings release on 03 Apr 2026. Financials show strained liquidity (current ratio 0.17) and large valuation multiples driven by near-zero revenue, so fundamentals do not support aggressive long positions without a clinical or corporate catalyst. Meyka AI rates OXUR.BR 72.79/100 (B+) and presents model outputs that point to outsized upside, but those projections carry high model risk for micro-cap biotech names. For risk-managed exposure, consider very small position sizes, predefined stop losses, and event-driven entries tied to trial updates or the earnings report. For a practical roadmap: conservative target €0.01, base target €0.02, and upside target €0.05 if positive clinical readouts arrive. See our live page for ongoing updates and realtime tools at Meyka OXUR.BR. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.